Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
947.4 INR | -0.40% | +2.74% | +37.46% |
Apr. 26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
Apr. 26 | Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream | MT |
Sales 2024 * | 193B 2.31B | Sales 2025 * | 210B 2.52B | Capitalization | 953B 11.43B |
---|---|---|---|---|---|
Net income 2024 * | 35.8B 429M | Net income 2025 * | 37.34B 448M | EV / Sales 2024 * | 4.88 x |
Net cash position 2024 * | 13.47B 162M | Net cash position 2025 * | 33.33B 400M | EV / Sales 2025 * | 4.37 x |
P/E ratio 2024 * |
26.4
x | P/E ratio 2025 * |
25.4
x | Employees | 23,026 |
Yield 2024 * |
0.61% | Yield 2025 * |
0.61% | Free-Float | 24.87% |
Latest transcript on Zydus Lifesciences Limited
1 day | -0.40% | ||
1 week | +2.74% | ||
Current month | -5.95% | ||
1 month | -6.85% | ||
3 months | +28.64% | ||
6 months | +65.83% | ||
Current year | +37.46% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 44 | 97-07-31 | |
Director of Finance/CFO | - | - | |
Chairman | 71 | 95-05-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 18-12-05 | |
Chairman | 71 | 95-05-14 | |
Director/Board Member | 69 | 97-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.22% | 6 M€ | +6.07% | - | |
0.01% | 117 M€ | +1.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 947.4 | -0.40% | 697,528 |
24-04-25 | 951.2 | +1.90% | 1,455,928 |
24-04-24 | 933.5 | -2.70% | 3,433,345 |
24-04-23 | 959.4 | -0.03% | 1,094,642 |
24-04-22 | 959.7 | +4.07% | 1,739,090 |
Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.46% | 11.43B | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B | |
-4.29% | 4.71B |
- Stock Market
- Equities
- ZYDUSLIFE Stock